The p53 protein has appropriately been named the "guardian of the genome". In almost all human cancers, the powerful tumor suppressor function of p53 is compromised by a variety of mechanisms, including mutations with either loss of function or gain of function and inhibition by its negative regulators MDM2 and/or MDMX. We review herein the progress made on different therapeutic strategies for targeting p53.
Keywords: MDM2; MDMX; PROTACS; Y220C; activators; degraders; inhibitors; molecular glue; mutant p53; wild-type p53.